CytoSorbents Corporation (CTSO)

[andy55q]

Dr. John Kellum, Dr. Peng, and our scientific collaborators at University of Pittsburgh Medical Center recently published a scientific article in the journal, Critical Care, entitled, “Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis, studies in a rat model”

In this follow-up article to a 2013 Molecular Medicine article, the researchers discuss the role that activated white blood cells (your “soldiers against infection”) play in causing organ injury and failure in sepsis when they migrate to the otherwise healthy unaffected organs and release a slew of toxic chemicals that are meant to kill bacteria. In this paper, they demonstrate that a simple 4 hour CytoSorb blood treatment (compared to a sham cartridge control) in septic rats increases the homing signal (cytokine concentration gradient) so that these activated white blood cells migrate to the site of infection and away from healthy organs. This resulted in a decrease in cell and organ injury as determined by microscopic analysis of lung, liver, and kidney tissue. This helps to again demonstrate a major way that CytoSorb may be able to help prevent or treat organ failure, the leading cause of death in the ICU, in critically-ill patients.